349 related articles for article (PubMed ID: 16773194)
1. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.
Million K; Horvilleur E; Goldschneider D; Agina M; Raguénez G; Tournier F; Bénard J; Douc-Rasy S
Int J Oncol; 2006 Jul; 29(1):147-54. PubMed ID: 16773194
[TBL] [Abstract][Full Text] [Related]
2. Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line.
Goldschneider D; Blanc E; Raguénez G; Barrois M; Legrand A; Le Roux G; Haddada H; Bénard J; Douc-Rasy S
J Cell Sci; 2004 Jan; 117(Pt 2):293-301. PubMed ID: 14676279
[TBL] [Abstract][Full Text] [Related]
3. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.
Zhang P; Liu SS; Ngan HY
PLoS One; 2012; 7(8):e42985. PubMed ID: 22900074
[TBL] [Abstract][Full Text] [Related]
4. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
[TBL] [Abstract][Full Text] [Related]
5. p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability.
Yan W; Zhang J; Zhang Y; Jung YS; Chen X
Mol Cell Biol; 2012 Jul; 32(13):2336-48. PubMed ID: 22508983
[TBL] [Abstract][Full Text] [Related]
6. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.
Tophkhane C; Yang SH; Jiang Y; Ma Z; Subramaniam D; Anant S; Yogosawa S; Sakai T; Liu WG; Edgerton S; Thor A; Yang X
PLoS One; 2012; 7(8):e43564. PubMed ID: 22952705
[TBL] [Abstract][Full Text] [Related]
7. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of platelet-derived growth factor beta-receptor expression by DeltaNp73 in neuroblastoma.
Wetterskog D; Moshiri A; Ozaki T; Uramoto H; Nakagawara A; Funa K
Mol Cancer Res; 2009 Dec; 7(12):2031-9. PubMed ID: 19952113
[TBL] [Abstract][Full Text] [Related]
10. Effects of ΔNp73β on cisplatin treatment in colon cancer cells.
Lööf J; Pfeifer D; Ding Z; Sun XF; Zhang H
Mol Carcinog; 2012 Aug; 51(8):628-35. PubMed ID: 21837762
[TBL] [Abstract][Full Text] [Related]
11. Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549.
He Y; Fan SZ; Jiang YG
Ai Zheng; 2006 Aug; 25(8):925-32. PubMed ID: 16965670
[TBL] [Abstract][Full Text] [Related]
12. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
[TBL] [Abstract][Full Text] [Related]
13. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria.
John K; Alla V; Meier C; Pützer BM
Cell Death Differ; 2011 May; 18(5):874-86. PubMed ID: 21127500
[TBL] [Abstract][Full Text] [Related]
14. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
Azmi AS; Aboukameel A; Banerjee S; Wang Z; Mohammad M; Wu J; Wang S; Yang D; Philip PA; Sarkar FH; Mohammad RM
Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675
[TBL] [Abstract][Full Text] [Related]
15. Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells.
Liu J; Uematsu H; Tsuchida N; Ikeda MA
Mol Cancer; 2011 Jul; 10():95. PubMed ID: 21801448
[TBL] [Abstract][Full Text] [Related]
16. p73gamma transactivates the p21 promoter through preferential interaction with the p300/CBP-associated factor in human prostate cancer cells.
Momii Y; Izumi H; Shiota M; Onitsuka T; Abe T; Kobayashi H; Miyamoto N; Uchiumi T; Kohno K
Oncol Rep; 2007 Aug; 18(2):411-6. PubMed ID: 17611664
[TBL] [Abstract][Full Text] [Related]
17. Variation in transcriptional regulation of cyclin dependent kinase inhibitor p21waf1/cip1 among human bronchogenic carcinomas.
Harr MW; Graves TG; Crawford EL; Warner KA; Reed CA; Willey JC
Mol Cancer; 2005 Jul; 4():23. PubMed ID: 16014176
[TBL] [Abstract][Full Text] [Related]
18. PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.
Hu ZB; Liao XH; Xu ZY; Yang X; Dong C; Jin AM; Lu H
Cancer Med; 2016 Jan; 5(1):74-87. PubMed ID: 26625870
[TBL] [Abstract][Full Text] [Related]
19. Induction of p21 and nuclear accumulation of TAp73alpha and c-abl during apoptosis of cisplatin-treated primary pancreatic acinar cells.
Sphyris N; Morris RG; Harrison DJ
Int J Oncol; 2004 Dec; 25(6):1661-70. PubMed ID: 15547703
[TBL] [Abstract][Full Text] [Related]
20. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
